Tempus AI, Inc. (NASDAQ:TEM) CAO Sells $66,969.66 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan M. Bartolucci sold 818 shares of the stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $81.87, for a total value of $66,969.66. Following the completion of the sale, the chief accounting officer now directly owns 46,182 shares in the company, valued at $3,780,920.34. This represents a 1.74 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Tempus AI Trading Down 11.2 %

NASDAQ:TEM opened at $68.09 on Friday. The stock’s 50 day moving average price is $50.29 and its 200 day moving average price is $51.72. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. First Horizon Advisors Inc. purchased a new position in Tempus AI during the 3rd quarter worth approximately $30,000. Operose Advisors LLC purchased a new position in shares of Tempus AI in the 4th quarter valued at approximately $25,000. Farther Finance Advisors LLC purchased a new position in shares of Tempus AI in the 4th quarter valued at approximately $34,000. Prestige Wealth Management Group LLC grew its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after purchasing an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in shares of Tempus AI in the 4th quarter valued at approximately $49,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Loop Capital dropped their price objective on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. TD Cowen reiterated a “buy” rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Guggenheim assumed coverage on Tempus AI in a report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective on the stock. Finally, Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.